Harbour Biomed announced a multispecific antibody collaboration with Bristol Myers Squibb that provides roughly $90 million up front and potential milestones exceeding $1 billion. The partnership will focus on discovery and development of multispecific antibody therapeutics. Harbour will combine its discovery platform with BMS development and commercialization capabilities. The deal underscores sustained big‑pharma appetite for acquiring or partnering with smaller firms that can advance multispecific and next‑generation biologic modalities.